UBE2C and ovarian cancer: Since a previous study reported that UBE2C could promote DDP resistance in ovarian cancer [17], cells were treated with different concentrations of DDP (0, 5, 10, 20, 40, and 80 μM) to investigate the effect of UBE2C on GC drug-resistance.